Ubs Oconnor LLC Bellus Health Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $49,351 - $58,959	6,912 Added 2.62%	271,161 $1.95 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $204,521 - $267,719	24,881 Added 10.39%	264,249 $0
Q3 2022 Nov 14, 2022	SELL	$8.95 - $12.0 $537,000 - $720,000	-60,000 Reduced 20.04%	239,368 $2.53 Billion
Q2 2022 Aug 12, 2022	BUY	$6.46 - $10.02 $803,417 - $1.25 Million	124,368 Added 71.07%	299,368 $2.77 Million
Q1 2022 May 16, 2022	BUY	$5.56 - $7.99 $972,999 - $1.4 Million	175,000 New	175,000 $1.2 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.